ArticleCancer discovery2018
Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.Nature communications · 2019Pooled it
- Insights from three decades of BRCA1/2 modeling in mice.Nature genetics · 2026Review
- Investigating the Mechanisms of Combined Therapy for MCF-7 Breast Cancer Cells Using Arsenic Trioxide and Resveratrol through Network Pharmacology.Phenomics (Cham, Switzerland) · 2025Article
- Landscape of gene fusions in hormone receptor-positive breast cancer reveals ADK fusions as drivers of progression and potential therapeutic targets.Cell discovery · 2025Article
- Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.International journal of molecular sciences · 2024Review
- Troponin T1 in tumorigenesis and immune modulation: Insights into multiple cancers and kidney renal clear cell carcinoma.Journal of cellular and molecular medicine · 2024Article
- Reciprocal antagonism of PIN1-APC/CNature communications · 2024Article
- The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.Nature reviews. Cancer · 2024Review
- Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories.Biomolecules · 2023Review
- Obesity promotes breast epithelium DNA damage in women carrying a germline mutation inScience translational medicine · 2023Article
- SB Digestor: a tailored driver gene identification tool for dissecting heterogeneous Sleeping Beauty transposon-induced tumors.International journal of biological sciences · 2023Article
- Is loss of p53 a driver of ductal carcinoma in situ progression?British journal of cancer · 2022Review
- Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids.Journal for immunotherapy of cancer · 2021Article
- FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance.Nature cell biology · 2021Article
- Review
- AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer.Breast cancer research : BCR · 2021Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
9 authors at 4 institutions in 1 country.
Hui Liu *Department of Pathology, and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Charles J Murphy *Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York.
Florian A KarrethDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Kristina B EmdalDepartment of Biological Engineering, Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Forest M WhiteDepartment of Biological Engineering, Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Olivier ElementoInstitute for Computational Biomedicine, Weill Cornell Medical College, New York, New York.
Alex TokerDepartment of Pathology, and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Gerburg M WulfDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Lewis C CantleyMeyer Cancer Center, Weill Cornell Medicine, New York, New York. lcantley@med.cornell.edu.
Beth Israel Deaconess Medical Center · USCornell University · USMassachusetts Institute of Technology · USMoffitt Cancer Center · US
Funding
Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI MYLES A BROWN · 2013 to 2026
$30.1MVariation in Receptor Tyrosine Kinases and Breast Cancer RiskP50CA089393 · NCI · DANA-FARBER CANCER INSTITUTE · PI HARRIS, LYNDSAY NORINE · 2000 to 2009
$28.8MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9MRole of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2MProject 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI ZIPFEL, WARREN R · 2016 to 2020
$10.2MThe Role of PI3K in Growth RegulationR01GM041890 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CANTLEY, LEWIS C. · 1990 to 2016
$4.1MThe identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma (Administrative Supplement)R01CA194547 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, TAM, WAYNE · 2015 to 2019
$2.6MThe joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor ProfilesU24CA210989 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, ZODY, MICHAEL C · 2016 to 2020
$2.4MOptimization of PI3K-inhibitors to augment the efficacy of microtubule-disrupting chemotherapyR01CA226776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WULF, GERBURG M · 2018 to 2022
$2.1MEPA EP-D-16-021NCI NIH HHS P50 CA089393NCI NIH HHS P50 CA168504NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA194547NCI NIH HHS R01 CA226776NCI NIH HHS R35 CA197588NCI NIH HHS U24 CA210989NCI NIH HHS U54 CA210184NIGMS NIH HHS R01 GM041890
Abstract
Triple-negative breast cancers (TNBC) are genetically characterized by aberrations in
Indexed as
MutationAnimalsBRCA1 ProteinExome SequencingFemaleGene FusionHumansMammary Neoplasms, ExperimentalMAP Kinase Signaling SystemMice, Mutant StrainsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-rafReceptor, Fibroblast Growth Factor, Type 2Sequence Analysis, RNATriple Negative Breast NeoplasmsTumor Suppressor Protein p53BRCA1 ProteinBrca1 protein, mouseFgfr2 protein, mousePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-rafReceptor, Fibroblast Growth Factor, Type 2Trp53 protein, mouseTumor Suppressor Protein p53Tumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.